TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06359197
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants would take two placebo pills to match the dosage of the intervention group. The investigators will use empty vegetable capsules from Health Bloom as the placebo for the control group. These capsules contain no contaminants or additives and are free from the common allergens. They are sugar-free-unlike most placebo pills, which reduces the confounding effect of sugar on our results. They are developed by Health Bloom, which is a Canadian company established in 2015. These capsules undergo testing at various stages of production to ensure purity and quality control. Each ingredient is tested prior to formulation, and the final capsules are subjected to thorough testing post-development. The capsules are white, and similar in appearance to the caffeine pill given to participants in the intervention group.
Study: NCT02358018
Drug: 68Ga-DOTATOC PET/CT Scan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study participants will undergo the 68Ga-DOTATOC PET/CT after informed consent. The nominal injected dose will be up 3-5.5 mCi containing approximately 10 - 50 microgram of 68Ga-DOTATOC and will be injected via IV access lines. CT scans will be performed with our standard oral contrast agent (typically Omnipaque and/or barium) in accordance with our standard FDG practice unless some contraindication is present. Uptake period following injection will be 0.75-1hour. Acquisition time will be approximately \~1 hour. In patients who may not be able to lie still, anesthesia will be provided as per routine standard clinical practice.
Study: NCT06118333
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral administration
Study: NCT04788186
Drug: De-prescribe beta blocker therapy
Normalized name: sangre de grado
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be de-prescribed for beta-blocker therapy.~De-prescription will be performed as follows:~* Half of pre-randomization dose for the first 3 days, then~* Half of the above dose for the next 3 days, then discontinue
Study: NCT06196697
Drug: XELOX
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will receive AK104 and AK112 in combination with XELOX(oxaliplatin and capecitabine)
Study: NCT04235322
Drug: 2LHERP®
Approvals — FDA: no, EMA: no, PMDA: no
Description: The treatment schema consists in taking the content of one capsule a day, 15-30 minutes before breakfast, on an empty stomach, sequentially, according to capsules' numerical order: 1 through 10. When capsule number 10 is taken, capsule 1 of the next blister should be taken on the next day to continue the treatment. The duration of treatment will be 6 months of continuous intake of the content of 1 capsule/day.
Study: NCT04235322
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The treatment schema consists in taking the content of one capsule a day, 15-30 minutes before breakfast, on an empty stomach, sequentially, according to capsules' numerical order: 1 through 10. When capsule number 10 is taken, capsule 1 of the next blister should be taken on the next day to continue the treatment. The duration of treatment will be 6 months of continuous intake of the content of 1 capsule/day.
Study: NCT05338866
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: For patients with AJCC stage II and III and age \< 72 years old, Capox ×6→capecitabine×2.~Detailed usage: Oxaliplatin 130mg/m2 (reduced to 100mg/m2 during concurrent chemoradiotherapy), intravenous administration, d1. Capecitabine 1000mg / m2, twice a day, d1-14. Repeated every 3 weeks.~For patients aged ≥ 72 years, or the competent physician judges that the patients cannot tolerate dual drug combined chemotherapy, capecitabine ×8 courses.~For patients with AJCC stage I, capecitabine ×4 courses.
Study: NCT00013923
Drug: Nutritional Supplement
Normalized name: Nutritional supplement
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05411380
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 500mg orally three times a day (continuously)
Study: NCT05411380
Drug: Endocrine Therapy
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anastrozole, 1mg, orally once daily or Letrozole, 2.5mg, orally once daily or Exemestane , 25mg, orally once daily or fulvestrant 500 mg each time, intramuscularly, injected on the 1st day and 15th day of the 1st cycle, and on the 1st day for subsequent cycle( 4 weeks for one cycle)
Study: NCT00282061
Drug: Melatonin
Normalized name: Melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT06207760
Drug: Minocycline
Normalized name: Minocycline
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Minocycline (200 mg/day) for 8 weeks with a single daily administration (2 hard capsules of 100 mg)
Study: NCT04987463
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo in liquid administered orally, once daily, in the morning. The starting dose of placebo in liquid will be calculated according to the body weight of the patient measured at V1.
Study: NCT04987463
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo in granules administered orally, initially once daily in the evening,and after reaching the targeted dose administered two times daily.
Study: NCT06155032
Drug: Best medical management
Approvals — FDA: no, EMA: no, PMDA: no
Description: All the patients enrolled received standard guideline-directed medical therapy including: monitor vital signs, management of blood pressure, glucose and lipids, antithrombotic (antiplatelet or anticoagulant therapy determined by treating physician) therapy if appropriate
Study: NCT04638803
Drug: PRX-P4-003, (-)-FCF
Approvals — FDA: no, EMA: no, PMDA: no
Description: sequential study
Study: NCT05398705
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Day 1\~5: placebo+SMT~SMT:standardized medical treatment according to Scheme for Diagnosis and Treatment of 2019 Novel Coronavirus Pneumonia (The 9th Trial Edition) from health commission of China, including bed rest, adequate energy and nutrition, pay attention to water and electrolyte balance to maintain a stable internal environment, closely monitor, antiviral drug and Chinese medicine treatment, etc.
Study: NCT06345014
Drug: OM-89 [Uro-Vaxom® Capsule]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration of the investigational product (OM-89 \[Uro-Vaxom® Capsule\] or the placebo) once a day
Study: NCT06345014
Drug: OM-89 Placebo [Uro-Vaxom® Capsule Placebo]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration of the investigational product(Placebo of Uro-Vaxom® Capsule)
Study: NCT04842552
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT05096598
Drug: ZP8396
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive 1 single dose of ZP8396 given subcutaneously (s.c., under the skin) or intravenously (i.v., in a vein of the arm). Dose level will depend on the cohort.
Study: NCT05096598
Drug: Placebo (ZP8396)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive 1 single dose of placebo given subcutaneously (s.c., under the skin) or intravenously (i.v., in a vein of the arm).
Study: NCT06174545
Drug: Pigment Solution Program
Approvals — FDA: no, EMA: no, PMDA: no
Description: adjuvant therapy for melasma that contains of combination formula consisting of morning cream - containing kojic acid, Vitamin E, Vitamin A and AquaxylTM complex; night cream - contains kojic acid, glycolic acid and AquaxylTM complex, scrub granules; and cleaning fluid containing vegetable oil and lactic acid.
Study: NCT05750628
Drug: INE963
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral INE963
Study: NCT05750628
Drug: KLU156
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral sachet KLU156 (KAF156 + lumefantrine)
Study: NCT04542434
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo tablets 3 times daily for 14 days
Study: NCT05732077
Drug: Dopamine
Normalized name: Dopamine
DrugBank: Dopamine (DB00988)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A bolus dose of 50μg/kg dopamine via renal artery to induce hyperemic status
Study: NCT05979207
Drug: MMV367
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose
Study: NCT05180890
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo intravenous infusion.
Study: NCT04876131
Drug: Gentamicin - single dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive a single dose of IV antibiotic (gentamicin).~Gentamicin dosing: Children ≤10 years old: 7.5 mg/kg (maximum dose 320 mg) Children \>10 years old: 6-7 mg/kg (maximum dose 560 mg)
Study: NCT04876131
Drug: Gentamicin - three days
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive three days of this IV antibiotic (gentamicin).~Gentamicin dosing: Children ≤10 years old: 7.5 mg/kg (maximum dose 320 mg) Children \>10 years old: 6-7 mg/kg (maximum dose 560 mg)
Study: NCT04876131
Drug: Cefalexin - post single dose of IV antibiotics for the remaining two days
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral antibiotic will be as per local guidelines. i.e. Cefalexin 25mg/kg (maximum dosage 500mg) 4 times a day or 33mg/kg (maximum dosage 500mg) 3 times a day
Study: NCT05192395
Drug: DWJ1525
Approvals — FDA: no, EMA: no, PMDA: no
Description: DWJ1525
Study: NCT05192395
Drug: DWP16001
Approvals — FDA: no, EMA: no, PMDA: no
Description: DWP16001
Study: NCT05192395
Drug: DWC202101
Approvals — FDA: no, EMA: no, PMDA: no
Description: DWC202101
Study: NCT04992624
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo drug will be taken similarly to the THC and CBD and be matched to keep the trial blinded.~In the event that 2.5 mg capsules of dronabinal capsules become unavailable, an equivalent product will be issued to participants and the comparator and placebo arms will be correspondingly adjusted to preserve blinding. If a participant's dose is not well-tolerated, the participant may initiate dose reductions with the study team.~Participants will be instructed to eat a meal or snack greater than one hour after taking study drug.
Study: NCT04801043
Drug: XNW4107
Approvals — FDA: no, EMA: no, PMDA: no
Description: XNW4107 250mg IV over 60 minutes as a single dose
Study: NCT04801043
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo to XNW4107 containing the same inactive ingredients IV over 60 minutes as a single dose~Matching placebo to Imipenem/Cilastatin 0.9% sodium chloride IV over 60 minutes as a single dose
Study: NCT05998837
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be add on RAAS-i titrated with the aim to reach optimal blood pressure control as defined by European Society of Hypertension (i.e., 120-130/70-80 mmHg) in all subject.~Prior to randomization all the patient with Type 2 Diabetes must have undergone at least 4 weeks of therapy with metformin and/or repaglinide
Study: NCT05805605
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered as a 2 hour IV infusion on day -6, +3, and +4.
Study: NCT04735796
Drug: Drug：LM-102
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional '3+3' escalation design will be used. Dose escalation consists of five ascending dose levels of LM-102 (3 mg/kg, 10 mg/kg, 20 mg/kg, 30 mg/kg and 40 mg/kg). All subjects will be administered every 3 weeks (1 cycle=21 days) with a dose of LM-102 as a 2 h (120±10 min) intravenous (IV) infusion until the disease progression, intolerance, subject discontinuation/informed consent withdrawal, or at the discretion of the investigator in consultation with sponsor, at most till by one year.
Study: NCT06180083
Drug: 'DYMISTA' NASAL SPRAY
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose \[four sprays (two sprays in each nostril)\] of 'DYMISTA' (AZELASTINE HYDROCHLORIDE/ FLUTICASONE PROPIONATE) NASAL SPRAY 137 Microgram/50 Microgram
Study: NCT06730932
Drug: JS004（BTLA monoclonal antibody，intravenously）,Toripalimab（ anti-PD-1specific antibody，intravenously)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant humanized anti-BTLA monoclonal antibody (JS004) injection 200mg via IV infusion once every 3 weeks~Toripalimab 240mg via IV infusion once every 3 weeks~JS004 will be administered in combination with toripalimab until disease progression or intolerable toxicity or up to 2 years of treatment or other reasons specified in the protocol
Study: NCT05318833
Drug: HRS7415
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: HRS7415
Study: NCT04968522
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo is Maize Starch and Pregelatinised Maize Starch. The placebo will be encapsulated using the same capsule that is opaque so that participants cannot distinguish the two visually. Where the active mediation amount is small for the capsule, there will be additional Starcke 1500 (Maize Starch and Pregelatinised Maize Starch) added to fill the capsule so that the active drug and capsule also weigh approximately the same. The dose of placebo will be matched to the participants currently prescribed stimulant medication.
Study: NCT05981014
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin will be administered at 60 mg/m\^2 IV on Day 1 of Cycles 1-2 of the neoadjuvant chemotherapy of the study.
Study: NCT05981014
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide will be administered at 600 mg/m\^2 IV on Day 1 of Cycles 1-2 of the neoadjuvant chemotherapy of the study.
Study: NCT05981014
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide will be administered at 60 mg/kg IV daily over approximately two hours for two days. Cyclophosphamide will be initiated seven days prior to the anticipated LNL transfer, and the precise timing will depend on the rate of in vitro LNL growth.
Study: NCT06188676
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ciclofosfamida
Study: NCT06188676
Drug: Doxorubicin Hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adriamycin
Study: NCT06188676
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolonum
Study: NCT05483465
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Visually identical pill to NR, daily per os for 8 weeks
Study: NCT04611776
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered intravenously during the induction phase and the maintenance phase.
Study: NCT04651166
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100mL saline or lactated ringers
Study: NCT05202015
Drug: MRI using a hepatobiliary phase contrast agent (Gd-EOB-DPTA)
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: MRI of the liver accoring to our institutional daily routine protocol
Study: NCT06006598
Drug: Placebo matching BI 1584862
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching BI 1584862
Study: NCT05633459
Drug: Multiple ascending doses of Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple ascending doses of placebo comparator will be intrathecally administered to individuals with sporadic ALS.
Study: NCT05633459
Drug: QRL-201
Approvals — FDA: no, EMA: no, PMDA: no
Description: QRL-201 will be intrathecally administered to individuals with C9orf72 ALS.
Study: NCT05683951
Drug: DWKH-R
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of DWKH-R three times daily
Study: NCT05683951
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of Placebo three times daily
Study: NCT04640376
Drug: Paracetamol Uniflash 125mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oromucosal solution 1.25 mL for buccal use
Study: NCT05363956
Drug: salvadora
Normalized name: SALVADORA PERSICA ROOT
Approvals — FDA: no, EMA: no, PMDA: no
Description: The participants were given a dentifrice that had been labeled and tagged with a number. All participants were asked to brush their teeth twice daily with a 1cm line of paste in their respective brushes for two minutes, once in the morning and the other at night, using the modified bass technique.
Study: NCT04640376
Drug: Panadol 500 MG Oral Tablet X1
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet masked in capsule
Study: NCT04640376
Drug: Panadol 500 MG Oral Tablet X2
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet masked in capsule
Study: NCT04640376
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dummy treatment
Study: NCT06154720
Drug: Antibiotics
Normalized name: Antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: After the woman had a repaired episiotomy following uncomplicated vaginal birth at 37 weeks or greater with no indication for ongoing antibiotics in the postpartum period. The patients were randomized to receive a co-amoxiclav 625mg (study group) tabs twice daily for 3 days after delivery or no antibiotic arm (control group).
Study: NCT04808414
Drug: QPX9003 for IV Infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: antibiotic
Study: NCT04808414
Drug: Placebo for IV infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo comparator
Study: NCT05639686
Drug: Total Intravenous Anesthesia
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Within 10 minutes of induction, patients in the control (TIVA) group will be administered a 100mL bolus of normal saline as placebo.
Study: NCT06345729
Drug: MK-1084
Normalized name: vitamin MK 7
DrugBank: MK-5108 (DB12556)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablets
Study: NCT06323395
Drug: Vizol S LIPID BALANCE eye drops
Normalized name: Luden's Drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 drop 4 times a day
Study: NCT06323395
Drug: ophthalmic saline eye drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 drop 4 times a day
Study: NCT05256069
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive a placebo in pill form.
Study: NCT05979896
Drug: Standard age based SPAQ administration for SMC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfadoxine-pyrimethamine and amodiaquine (SPAQ) is administered in standard WHO approved age based regimens as used in Seasonal Malaria Chemoprevention Programmes.~Sulphadoxine is a slowly eliminated sulphonamide. It is used in a fixed dose combination of 20 parts sulphadoxine with 1 part pyrimethamine given orally or intramuscularly.~Sulphadoxine is readily absorbed from the GIT. It is widely distributed in body tissues and fluids and crosses the placenta into foetal circulation. It is also readily detectable in breast milk. It is excreted predominantly as the unchanged drug. AQ Amodiaquine is a Mannich base 4 amino-quinoline that interferes with parasite haem detoxification. It is more effective than chloroquine in both chloroquine sensitive and resistant P. falciparum infections. However, there is cross-resistance between chloroquine and amodiaquine.~It is readily absorbed in the GIT and rapidly converted in the liver to the active metabolite, desethylamodiaquine.
Study: NCT05132790
Drug: SHR-1316 at a dose 20mg/kg q3w
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of SBRT and SHR1316, followed by SHR1316 plus nab-paclitaxel and carboplatin or cisplatin
Study: NCT05132790
Drug: SHR6390 at a dose of 150mg orally, daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR6390 plus exemestane with/without ovarian function suppression/ablation (OFS) after SBRT
Study: NCT06323213
Drug: 610
Normalized name: AY-6108
Approvals — FDA: no, EMA: no, PMDA: no
Description: 610 subcutaneously injection.
Study: NCT06323213
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo subcutaneously injection.
Study: NCT05122780
Drug: Statin
Normalized name: Statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.e. atorvastatin; dosages titrated on the patient's clinical characteristics
Study: NCT05122780
Drug: Beta blocker
Normalized name: Beta blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.e. bisoprolol; dosages titrated on blood pressure, ECG, heart rate
Study: NCT05122780
Drug: ACEi/ARB
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.e. ramipril; dosages titrated on blood pressure, ECG, heart rate
Study: NCT05122780
Drug: CCB
Normalized name: olive/homosal/ccb/coco oil/alm TOPICAL OIL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.e. diltiazem; dosages titrated on blood pressure, ECG, heart rate
Study: NCT05474755
Drug: GP681 40mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2X20mg tablets taken orally
Study: NCT05474755
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets matching GP681 40mg
Study: NCT05712837
Drug: 25% TRICHLOROACETIC ACID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients of group A were treated with 25% TCA peel and patients at 2-week intervals for a total of 12 weeks. Clinical evaluation was done at the end of therapy after 12-weeks of treatment.
Study: NCT00954200
Drug: ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: ibuprofen 10mg/kg syrup, single dose vs placebo
Study: NCT00954200
Drug: ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 10mg/kg syrup - single dose
Study: NCT05635877
Drug: Placebo Comparator: Placebo Comparator:normal saline(0.9%)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The control group received the same volume of 0.9% normal saline, which was continuously pumped until the end of the operation before extubation.Patient-controlled analgesia pump (sufentanil 2 μg/kg, 2 mL/h, for 48h) was used as the postoperative analgesia regimen in the two groups. If the VAS score was \>3, analgesic adjuvant drugs were given intravenously and recorded. If repeated treatment is ineffective, the study will be excluded.
Study: NCT04893187
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo.
Study: NCT05223166
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo tablets will be provided for each strength of active pitolisant film-coated tablets.
Study: NCT06567327
Drug: Danuglipron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danuglipron oral tablets